PE20010580A1 - Composicion farmaceutica para tratar la diabetes - Google Patents

Composicion farmaceutica para tratar la diabetes

Info

Publication number
PE20010580A1
PE20010580A1 PE2000000887A PE0008872000A PE20010580A1 PE 20010580 A1 PE20010580 A1 PE 20010580A1 PE 2000000887 A PE2000000887 A PE 2000000887A PE 0008872000 A PE0008872000 A PE 0008872000A PE 20010580 A1 PE20010580 A1 PE 20010580A1
Authority
PE
Peru
Prior art keywords
alkyl
alcoxycarbonyl
carboxyl
pharmaceutical composition
ora
Prior art date
Application number
PE2000000887A
Other languages
English (en)
Inventor
Katsuichi Sudo
Yasuhiko Wada
Yasuo Sugiyama
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20010580A1 publication Critical patent/PE20010580A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA EN COMBINACION CON a)UN COMPUESTO I, R1 ES ALQUILO SUSTITUIDO POR OH, FENILSULFONILAMINO, ALQUILSULFONILAMINO, MONOALQUILAMINOSULFONILO, XaRa, -[O(CH2)p-CH(Rb)]qRbb, -O(CH2)r-Rc, Ya-(CH2)s-Rd O JUNTO CON R2 FORMA METILENDIOXILO OPCIONALMENTE SUSTITUIDO POR CARBOXILO, ALCOXICARBONILO, Ra ES H, ALQUILO, Ra ES ALQUILO CUANDO Xa ES S, Rb ES H, ALQUILO, ALCOXICARBONILO, CARBOXILO, Rbb ES ALCOXICARBONILO, CARBOXILO, p ES 0-3; q ES 0-1; Rc ES ALCANOILO, HIDROXILO, CIANO, FENILO, ALQUILAMINOCARBONILO, P(=O)(ORA)(ORA), RA ES H, ALQUILO; r ES 1-4; Ya ES HN, S, Rd ES CARBOXILO, ALCOXICARBONILO; s ES 1-4; R2 ES H, HALOGENO, ALQUILO, OH, ALCOXILO; R3 ES H, ALQUILO; W ES 2-, 3-INDOL; b)UN COMPUESTO IV, R ES UN HIDROCARBURO, HETEROCICLO; Y ES CO, CHOH, NR3; R3 ES ALQUILO; m ES 0-1; n ES 0-2; X ES CH, N; A ES UN ENLACE, HIDROCARBURO; Q ES O, S; R1 ES H, ALQUILO; L Y M SON H DE PREFERENCIA ES PIOGLITAZONA, ROSIGLITAZONA, EN COMBINACION CON 2-[3-(7-CARBOXIMETOXIINDOL-3-IL)-(2R)-2-PROPILAMINO]-(1R)-1-(3-CLOROFENIL)ETANOL. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DIABETES, TOLERANCIA A GLUCOSA DISMINUIDA, HIPERLIPIDEMIA, HIPERINSULINEMIA, OBESIDAD, HIPERFAGIA, HIPERTENSION, RETINOPATIA, NEFROPATIA, PARA INHIBIR EL AUMENTO DE PESO
PE2000000887A 1999-09-03 2000-08-29 Composicion farmaceutica para tratar la diabetes PE20010580A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25044399 1999-09-03
JP2000056021 2000-02-28

Publications (1)

Publication Number Publication Date
PE20010580A1 true PE20010580A1 (es) 2001-05-25

Family

ID=26539777

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000887A PE20010580A1 (es) 1999-09-03 2000-08-29 Composicion farmaceutica para tratar la diabetes

Country Status (14)

Country Link
EP (1) EP1212090A2 (es)
KR (1) KR20020063555A (es)
CN (1) CN1372476A (es)
AR (1) AR031674A1 (es)
AU (1) AU6868000A (es)
CA (1) CA2383946A1 (es)
CO (1) CO5180632A1 (es)
HK (1) HK1044711A1 (es)
HU (1) HUP0203285A3 (es)
NO (1) NO20021036L (es)
PE (1) PE20010580A1 (es)
PL (1) PL354295A1 (es)
RU (1) RU2002108346A (es)
WO (1) WO2001017513A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354602B1 (en) 2000-12-26 2006-10-04 Sankyo Company, Limited Medicinal compositions containing diuretic and insulin resistance-improving agent
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
AU2003242245A1 (en) * 2002-06-12 2003-12-31 Sumitomo Pharmaceuticals Co., Ltd. Indole, indazole, and benzazole derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701152A (ko) * 1988-11-14 1992-08-11 로버트 에이. 아미테이지 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산
CA2071629C (en) * 1990-02-09 1997-12-30 Jerry R. Colca Use of insulin sensitizing agents to treat hypertension
RO118426B1 (ro) * 1994-11-29 2003-05-30 Dainippon Pharmaceutical Co Derivati de indol utilizati pentru tratarea diabetului zaharat si a obezitatii

Also Published As

Publication number Publication date
WO2001017513A2 (en) 2001-03-15
HUP0203285A3 (en) 2003-02-28
WO2001017513A3 (en) 2001-09-20
EP1212090A2 (en) 2002-06-12
CA2383946A1 (en) 2001-03-15
NO20021036D0 (no) 2002-03-01
KR20020063555A (ko) 2002-08-03
CN1372476A (zh) 2002-10-02
HK1044711A1 (zh) 2002-11-01
AU6868000A (en) 2001-04-10
CO5180632A1 (es) 2002-07-30
HUP0203285A2 (hu) 2003-01-28
PL354295A1 (en) 2004-01-12
RU2002108346A (ru) 2003-11-20
AR031674A1 (es) 2003-10-01
NO20021036L (no) 2002-04-26

Similar Documents

Publication Publication Date Title
RU2312106C2 (ru) Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar
KR950702982A (ko) 치환된 티아졸리딘디온 유도체(Substituted Thiazolidinedione Derivatives)
JP2002316932A (ja) エストロゲンアゴニスト／アンタゴニストを使用する特定の癌の処置方法
RU2003137825A (ru) Пираноиндазолы и их использование при лечении глаукомы
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
UY24543A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol- 3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
DE69530094D1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
ATE420090T1 (de) Chemokine-rezeptor-antagonisten und methoden zu deren anwendung
CY1107500T1 (el) Η χρηση του φλουμαζενιλ στην αναπτυξη ενος φαρμακου για τη θepαπευτικη αντιμετωπιση της εξαρτησης απο το αλκοολ
CO5440230A1 (es) Nuevo compuesto heterociclico que comprende tetrahidroisoquinolina y una sal farmaceuticamente aceptable del mismo
PE20010580A1 (es) Composicion farmaceutica para tratar la diabetes
RU2008126389A (ru) Производные 1,1- диоксотиоморфолинилиндолилметанона для применения в качестве модуляторов гистаминаз(н3)
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
KR960700696A (ko) 정맥성 질환 치료에 유용한 5-하이드록시트립타민-2 수용체 길항물질 조성물(5-ht₂receptor antagonist compositions useful in treating venous conditions)
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
ATE254122T1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
KR900700098A (ko) 발기부전의 치료겸 진단용 플라복세이트 및 그 유도체
DE50312523D1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
CN1111408C (zh) 药物滥用疾病治疗中的吡啶基－和嘧啶基－哌嗪类化合物
CN101163477A (zh) 多介质多巴胺转运抑制剂，以及其相关应用
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed